Frankfurt - Delayed Quote USD

BioCardia, Inc. (6JU0.F)

Compare

0.0000

-4.2600

(-100.00%)

As of May 30 at 8:52:31 AM GMT+2. Market Open.

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of participants treated in low dosage group. The company plans to progress the trial to enrollment of 39 participants in the United States. SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that t

GlobeNewswire yesterday

BCDA

BCDAW
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, Department of Medicine, Emory University School of Medicine, and Co-Director of the Emory Clinical Cardiovascular Research Institute to Serve as Principal Investigator SUNNYVALE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA

GlobeNewswire 5 days ago

BCDA

BCDAW
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. To access the call today:Participants can register fo

GlobeNewswire 16 days ago

BCDA

BCDAW
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significanceStatistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with CardiAMP Cell TherapyPatient improvements through two years suggest single dos

GlobeNewswire 16 days ago

BCDA

BCDAW
BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioCardia ( NASDAQ:BCDA ) Full Year 2024 Results Key Financial Results Net loss: US$7.95m (loss narrowed by 31% from FY...

Simply Wall St. 19 days ago

BCDA

BCDAW
BioCardia Reports 2024 Business Highlights and Financial Results

SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2024 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will host a corporate update conference call on Monday, March 31, 2025 at 4:30 PM ET following its presentation of results from the

GlobeNewswire 21 days ago

BCDA

BCDAW
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2024 on Wednesday, March 26, 2025, and will host a corporate update conference call on Monday, March 31, 2025 (time and dial-information to be announced). The conference call will follow the presentation, “A Double-

GlobeNewswire 26 days ago

BCDA

BCDAW
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on or after September 30, 2034. “This new patent in Japan adds to our growing patent position with respect to minimally

GlobeNewswire last month

BCDA

BCDAW
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

SUNNYVALE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the completion of source data verification and freezing of primary outcomes data in the double-blind randomized placebo-controlled Phase 3 CardiAMP HF study of its autologous minimally invasive cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (

GlobeNewswire last month

BCDA

BCDAW
BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Focus on Patients with Elevated Markers of Heart Stress and Inflammation Procedural enhancement using FDA Approved Morph DNA steerable guide for therapeutic delivery SUNNYVALE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today completion of enrollment and dosing in the low dose cohort in its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Ph

GlobeNewswire 2 months ago

BCDA

BCDAW
BioCardia upgraded to Buy from Neutral at Alliance Global Partners

Alliance Global Partners analyst James Molloy upgraded BioCardia (BCDA) to Buy from Neutral with a $6 price target The company recently announced multiple clinical updates regarding its lead CardiAMP cell therapy platform BCDA-01, which has completed the last patient follow-up and should report final 24-month data in Q1, the analyst tells investors in a research note. The firm cites potential positive upcoming catalysts in Q1 and the stock’s “low current valuation” for the upgrade. Published fir

TipRanks 2 months ago

BCDA

BCDAW
BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have been accepted for presentation in a late-breaking symposium at the American College of Cardiology 2025 Scientific Sessions, taking place in Chicago, March 29-31, 2025. Title: A Double Blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the Ca

GlobeNewswire 2 months ago

BCDA

BCDAW
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

SUNNYVALE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the commercial availability of its Morph DNA steerable introducer product family, currently utilized in the Company’s ongoing cell-therapy clinical trials. “Our team is exploring an initial sales pipeline organically, without expending the operating costs associated with engaging

GlobeNewswire 3 months ago

BCDA

BCDAW
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Next PMDA Consultation after Review of CardiAMP HF Trial DataSUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the successful completion of a consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) on the next steps for the submission for registration of its lead therapeutic asset, BCDA-01, for the treatment of

GlobeNewswire 4 months ago

BCDA

BCDAW
BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)

BioCardia ( NASDAQ:BCDA ) Third Quarter 2024 Results Key Financial Results Net loss: US$1.74m (loss narrowed by 33...

Simply Wall St. 4 months ago

BCDA

BCDAW
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

SUNNYVALE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2024 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss busi

GlobeNewswire 4 months ago

BCDA

BCDAW
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants

GlobeNewswire 5 months ago

BCDA

BCDAW
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

SUNNYVALE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the completion of its last protocol specified follow-up visit in CardiAMP HF, a prospective, randomized, double-blinded, placebo procedure controlled, multi-center pivotal clinical trial for the treatment of heart failure of reduced ejection fraction (HFrEF). The CardiAMP HF Trial

GlobeNewswire 5 months ago

BCDA

BCDAW
BioCardia Regains Full Compliance with Nasdaq Listing Requirements

SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market’s Listing Requirements as required by the Hearing Panel’s (the “Panel”) decision on May 13, 2024. On September 17, 2024, BioCardia received notice from Nasdaq confirming that the Company has demonstrated

GlobeNewswire 6 months ago

BCDA

BCDAW
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the closing of its upsized public offering with participation from management and directors, institutional investors, and certain existing investors of the Company for the purchase and sale of 2,400,000 shares of common stock (or pre-funded warrants in lieu thereof) and warrants

GlobeNewswire 7 months ago

BCDA

BCDAW

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioCardia, Inc. (6JU0.F)

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioCardia Reports 2024 Business Highlights and Financial Results

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia upgraded to Buy from Neutral at Alliance Global Partners

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules